2015 APHA Annual Meeting & Expo

Home Events & Meetings Annual Meeting Schedule & Program

Recorded Annual Meeting Presentations (RAMP) are now available for purchase.
Only $90 for presenters, $140 for registered attendees and $200 for non-attendees.

Online Program

338247
Using Genetics to Optimize Treatment of Opiate Addiction – Current and Emerging Genetic Markers


Tuesday, November 3, 2015 : 11:30 a.m. - 11:50 a.m.

Naissan Hussainzada, PhD, Millennium Research Institute, Millennium Health, San Diego, CA

Audio (mp3) recording Recorded Presentation (mp4)
The program will provide an introductory overview of genetic considerations in opiate addiction, with a specific focus on pharmacogenetic options to help the clinician match their patient to the optimal medication therapy. Clinical scenarios will be presented to help illustrate utility of specific genetic biomarkers in guiding medication-assisted addiction therapy, including methadone and naltrexone. Emerging pharmacogenetic markers will also be discussed in the context of level of evidence.

Learning Areas:

Clinical medicine applied in public health
Public health or related research

Learning Objectives:
Identify genetic markers that may be used to optimize treatment of opiate addiction

Keyword(s): Drug Abuse Treatment, Research

Presenting author's disclosure statement:

Qualified on the content I am responsible for because: Naissan Hussainzada is Director, Pharmacogenetic Testing Clinical Strategy, Millennium Health. Principal Investigator, Millennium Research Institute. She is an educator and researcher in the areas of pharmacology and translational pharmacogenetics, with extensive experience lecturing at the regional and national level on topics including addiction, mental health disorders and chronic pain. I am currently conducting research evaluating associations between genetic markers and clinical outcomes in patients receiving therapy for various chronic conditions, including addiction.
Any relevant financial relationships? No

I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.

Back to: 4099.0: Iatrogenic Dependence – How to Effectively Address the Next Wave in Opioid Abuse – Heroin